Tandem Capital Management Corp ADV Acquires Shares of 817 argenex SE $ARGX

Key Points

• Tandem Capital Management Corp ADV has acquired a new stake in argenex SE, purchasing 817 shares valued at approximately $450,000 during the second quarter.
• Several institutional investors have recently increased their shares in argenex SE, leading to a total of 60.32% of the company's stock being held by hedge funds and other institutional investors.
• Analysts have given argenex a consensus rating of "Buy", with a reported average target price of $802.90, indicating strong market confidence in the company's performance.

Tandem Capital Management Corp ADV purchased a new stake in shares of argenex SE (NASDAQ:ARGX - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 817 shares of the company's stock, valued at approximately $450,000.

Other institutional investors have also recently made changes to their positions in the company. Rakuten Securities Inc. boosted its holdings in shares of argenex by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after acquiring an additional 22 shares during the last quarter. WPG Advisers LLC purchased a new stake in shares of argenex during the 1st quarter valued at about $37,000. Golden State Wealth Management LLC purchased a new stake in shares of argenex during the 1st quarter valued at about $44,000. Brooklyn Investment Group boosted its holdings in shares of argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company's stock valued at $44,000 after acquiring an additional 38 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new stake in shares of argenex during the 1st quarter valued at about $62,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ARGX shares. Stifel Nicolaus set a $882.00 price target on shares of argenex in a report on Thursday, September 18th. Jefferies Financial Group set a $818.00 price objective on shares of argenex and gave the stock a "buy" rating in a report on Tuesday, August 26th. Weiss Ratings reissued a "hold (c)" rating on shares of argenex in a report on Wednesday. Guggenheim reissued a "buy" rating and issued a $1,070.00 price objective on shares of argenex in a report on Thursday, September 18th. Finally, HC Wainwright raised their price objective on shares of argenex from $720.00 to $774.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $802.90.

argenex Price Performance

ARGX opened at $798.94 on Thursday. The firm has a market cap of $48.90 billion, a P/E ratio of 40.97, a PEG ratio of 0.87 and a beta of 0.46. argenex SE has a 1-year low of $510.05 and a 1-year high of $807.91. The company has a 50 day simple moving average of $714.80 and a two-hundred day simple moving average of $624.77.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. Equities analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.